Blog
Private Investors converge for BioSolution Designs’ Showcase with Opus8
Wednesday, January 17th, 2024 – Accredited Biotech/Biomedical investors gathered in Tysons Corner, Virginia, for a private, in-person presentation and dinner featuring FITCI startup client BioSolution Designs, Inc. (BSD), thanks to our ecosystem partner Opus8. Dozens listened while BSD CEO Sam Glickstein shared details about the rising company and its exciting potential both financially and as … Read more
Precision Painting Power: Transforming Spaces with Color and Care
Kevin Christmon always knew he wanted to make a difference. As a child, he saw the world as wide open, full of beauty and potential. He recalls fond memories of helping his granddad paint their house and realizing how a simple change of color could transfigure and re-energize a space. That feeling of being able … Read more
NanoBioFAB Interns Develop Pitch & Plan for Next Generation Business
Source: NanoBioFAB For half a decade, NanoBioFAB has shaped the future of tech leaders and entrepreneurs through its annual summer internship program. The Mission is clear: To harness the power of NanoBioFAB AI and nanosensor technology to fuel the growth of future innovators. This transformative program welcomes a diverse range of participants, from ambitious Urbana … Read more
BioFactura Funded $16 Million Contract Option for its Smallpox Biodefense Therapeutic
FITCI Grad BioFactura’s monoclonal antibody-based product has the potential to fulfill an unmet need. BioFactura, Inc. today announced a contract option activation of over $16 million by the Biomedical Advanced Research and Development Authority (BARDA) part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, as part … Read more
Theradaptive Awarded DOD Clinical Trial Award of up to $7.4 Million
FITCI Grad builds upon an unprecedented three Breakthrough Medical Device designations by the FDA Theradaptive, a leading biopharmaceutical company using protein engineering to create targeted therapeutics, has been awarded a U.S. Department of Defense (DOD) Clinical Trial Award of up to $7.4M with options, subject to FDA approval to begin phase I/II clinical studies. Awarded … Read more
Celebrating an Entrepreneurial Legacy
Alison Demarest & Thomas Blake of PACE Life Sciences Retire Congratulations to Alison Demarest & Thomas Blake of PACE Life Sciences on their retirement. This dynamic duo founded Meridian BioGroup in 2007 after nearly a year of planning, offering expert validation, regulatory, and compliance contract services to the biotechnology and pharmaceutical industries. In 2012, their … Read more
Welcome, Unraveling Obesity: Tackling the Complexities of a Global Epidemic
Obesity. It’s a word we hear all too often in today’s society. The prevalence of obesity has reached alarming levels, with the Centers for Disease Control and Prevention’s most recent survey revealing that 41.9% of Americans are living with this medical condition (2020 NHANES). This figure has risen significantly from 30.1% just two decades ago. … Read more
FITCI launches IDEA Lab for earliest-stage entrepreneurs
Budding entrepreneurs and seasoned business leaders gathered at FITCI’s ROOT location in downtown Frederick, Mayrland, for the first installment of the incubator’s newest community program, the IDEA Lab, sponsored by the Truist Foundation. Session leader/mentor Robert “Bob” Stoneking of Pachydermos began the evening event by telling participants, “the purpose of the IDEA Lab is not … Read more
CarrTech Corporation Performs Human Factor Trials
CarrTech Corporation performed its human factor trials with local healthcare professionals at FITCI’s Metropolitan Court location May 17th through 28th, moving their all-in-one package filter and hypodermic needle product, F.R.O.G (filter removal of glass), closer to market. This practical testing enlisted 20 study participants with experience using glass ampoule-based medications (i.e., #physicians, #pharmacists, #nurses). The … Read more
Osprey BioScience launches CloneCard
Sam Glickstein, CEO of FITCI client Osprey BioScience, announced that the company officially launched their flagship product – CloneCard. The patent-pending item is a proprietary nucleic acid storage and delivery (at room temperature) system. It offers researchers the ability to start building multi-genic and multi-modal therapeutic candidates modularly, in less time and with lower costs. … Read more